Collegium Pharma (COLL) Reports Q1 Loss of $1.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
August 10, 2016 4:01 PM EDTReceived FDA approval for Xtampza® ER, Companys lead opioid analgesic with abuse-deterrent propertiesAnnounced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study comparing effect of physical manipulation of Xtampza ER with the abuse-deterrent version of OxyContin®Reported positive results from a clinical study evaluating Hydrocodone DETERx® as a second product candidateLicensed U.S. rights to commercialize ONSOLIS® (fentanyl buccal soluble film) from BioDelivery Sciences International
CANTON, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:... More
